This $1,561,794 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research at the University of Cincinnati on plasmacytoid dendritic cells (pDCs) as a target for improving treatment of acute myeloid leukemia. The award commences on September 1, 2024 and has an ultimate completion date of August 31, 2027. The University of Cincinnati, through its Sponsored Research Services division, will serve as the prime recipient to execute this biomedical research project focused on advancing scientific understanding and therapeutic approaches related to the immunosuppressive role of pDCs in acute myeloid leukemia.
Generated 3/25/25, 4:43 AM